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Abstract: Patients with inactive or occult hepatitis B virus infection and onco
malignancies are at risk of hepatitis flare, hepatic failure and death due to chemotherapy
mediated reactivation. Nucleot(s)ide analogues can reduce reactivation risks and/or hepatitis. 
However,  immuno-mediated  phenomena  combine  to  determine
outcome. We describe in this report two patients with onco
hepatitis  B  reactivation  after  chemotherapy  in  whom  glucocorticoids  were  added  to 
nucleot(s)ide. Antiviral therapy was effective on replica
hyperergic response. One patient without underlying liver disease survived, while the second 
died  and  the  autopsy  demonstrated  cirrhosis  undetected  before  death.  This  clinical  trial 
suggests that in patients with onco
in spite of effective antiviral response, glucocorticoids could control the effects of immune 
response. However prognosis and survival are related to the underlying liver status.
Introduction: In overt or occult HBV carriers with 
onco-hematological malignancies, viral reactivation 
can be a consequence of chemotherapy, influencing 
the risk of developing hepatitis flare, 
and death.
1 Nucleot(s)ide analogues (NUC) are used 
to reduce the risk of reactivation in overt carriers 
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Patients with inactive or occult hepatitis B virus infection and onco
malignancies are at risk of hepatitis flare, hepatic failure and death due to chemotherapy
mediated reactivation. Nucleot(s)ide analogues can reduce reactivation risks and/or hepatitis. 
mediated  phenomena  combine  to  determine liver  damage  and  clinical 
outcome. We describe in this report two patients with onco-hematological malignancies and 
hepatitis  B  reactivation  after  chemotherapy  in  whom  glucocorticoids  were  added  to 
nucleot(s)ide. Antiviral therapy was effective on replication, while glucocorticoids managed 
hyperergic response. One patient without underlying liver disease survived, while the second 
died  and  the  autopsy  demonstrated  cirrhosis  undetected  before  death.  This  clinical  trial 
suggests that in patients with onco-hematological malignancies and altered liver function tests 
in spite of effective antiviral response, glucocorticoids could control the effects of immune 
response. However prognosis and survival are related to the underlying liver status.
In overt or occult HBV carriers with 
hematological malignancies, viral reactivation 
chemotherapy, influencing 
the risk of developing hepatitis flare, hepatic failure 
Nucleot(s)ide analogues (NUC) are used 
to reduce the risk of reactivation in overt carriers 
controlling viral replication. Prophylaxis in HBsAg
negative/anti-HBc-positive remains controversial.
Nevertheless,  immuno-
occurring as the result of the host’s immune system 
reconstitution  after  chemotherapy,  also  concur  to 
determine the  extent of liv
outcome.
2  No  clear  indications  exist  for  the 
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Patients with inactive or occult hepatitis B virus infection and onco-hematological 
malignancies are at risk of hepatitis flare, hepatic failure and death due to chemotherapy-
mediated reactivation. Nucleot(s)ide analogues can reduce reactivation risks and/or hepatitis. 
liver  damage  and  clinical 
hematological malignancies and 
hepatitis  B  reactivation  after  chemotherapy  in  whom  glucocorticoids  were  added  to 
tion, while glucocorticoids managed 
hyperergic response. One patient without underlying liver disease survived, while the second 
died  and  the  autopsy  demonstrated  cirrhosis  undetected  before  death.  This  clinical  trial 
matological malignancies and altered liver function tests 
in spite of effective antiviral response, glucocorticoids could control the effects of immune 
response. However prognosis and survival are related to the underlying liver status.
controlling viral replication. Prophylaxis in HBsAg-
positive remains controversial.
1
-mediated  phenomena, 
occurring as the result of the host’s immune system 
reconstitution  after  chemotherapy,  also  concur  to 
determine the  extent of liver  damage and clinical 
r  indications  exist  for  the Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 1. Timeline of disease evolution. Case 1.
Date
ALT
(U/l)
Bilirubin
(mg/dl)
Prothrombin time
(INR)
HBV DNA
(IU/ml)*
Therapy
17/07/2007 610 1,7 1,1 266.700 LAM 300 mg
20/07/ 2007 767 1,5 1,7 119.700
25/07/2007 1367 2,5 1,9 45.255
08/08/2007 2004 12,22 2 31.000 LAM 300 mg + ADV 10 mg + PDN 50 mg
13/08/ 2007 875 13,5 1,4 Nd
16/08/ 2007 732 8,8 1,07 Nd
23/08/ 2007 572 5,4 0,9 1.963
28/08/ 2007 333 3,3 0,9 Nd LAM 100 mg + ADV 10 mg + PDN 30 mg
19/09/2007 96 1,8 1.1 Negative
28/10/ 2007 22 1,2 0.9 Negative
ALT:  serum  alanine  aminotransferase; INR:  international  normalized  ratio;  LAM:  lamivudine;  ADV:  adefovir  dipivoxil;  PND: 
prednisolone; Nd: Not determined; * Amplicor Roche PCR, Lower limit of detection <40 IU/ml.
management of patients with HBV reactivation in 
whom biochemical disorders remain and the clinical 
course deteriorates, in spite of an effective control 
over viral replication obtained with NUC, possibly 
as  the  result  of  this  immuno-mediated  hyperergic 
response.
2 Glucocorticoids  have  been  sporadically 
used  to  control  the  immuno-mediated  effects  of 
HBV  reactivation,
3,4 but  their  role  in  the 
management  strategies  of  patients  with  onco-
hematological malignancies has  not  been  defined. 
Underlying liver disease status could also influence 
clinical  events  and  survival,  with  more  advanced 
liver disease determining the worst outcomes .
1 Our  
report  consists  of  two  patients  with  onco-
hematological malignancies and HBV reactivation 
in  whom  glucocorticoids  were  added  to  NUC  to 
manage reactivation. 
Case reports
Case  1:  In  July  2006  a  73  year-old  man  was 
diagnosed with myelo-monoblastic acute leukemia 
(AML-M4). Before chemotherapy, ultrasound (US) 
study of the liver, serum alanine aminotransferase 
(ALT),  total  bilirubin,  International  Normalized 
Ratio  (INR)  were  normal; anti-HCV,  HBsAg  and 
HBV-DNA were negative, anti-HBc, anti-HBs and 
anti-HBe positive. HBV monitoring was instituted 
[1].  FLANG  (fludarabine,  aracytin,  novantrone) 
was  administered  (August  2006-January  2007), 
which resulted in the patient going into remission. 
The patient did not attend the scheduled follow up 
visit for personal reasons, and in July 2007, sero-
reversion to HBsAg and increased ALT levels were
detected  and  he  was  admitted  to  the  Liver  Unit. 
Table 1 summarizes disease course. ALT were >15 
times  higher  than  the  upper  normal  value,  HBV-
DNA  positive  (266,700  IU/mL),  US  study  of  the 
liver was normal. High dose lamivudine (LAM, 300 
mg/day) was started immediately due to significant 
viremia and the diagnosis of leukemia. Twenty days 
later bilirubin, ALT and INR increased in spite of 
HBV-DNA  decrease  to  31,000  IU/mL;  firstly 
Adefovir (ADV) and then prednisolone (PDN, 50 
mg/day)  were  added  to  LAM,  speculating  that  a 
hyperergic immune response was the cause of liver 
damage  and  jaundice.  ADV  (10  mg/day)  was 
introduced to  control mutants eventually  escaping 
LAM. ALT, bilirubin, and INR began to improve 
after  three  days  with  the  introduction  of  PDN. 
HBV-DNA became negative one month later, and 
biochemical profile normalized after two months of 
treatment. During this period LAM and PDN were 
reduced  to  100  and  30  mg/day  respectively,  and 
ADV  continued.  Thereafter,  PDN  was  further 
reduced  and  discontinued  in  November, 
maintaining  LAM  and  ADV.  In  May  2008,  the 
patient  reverted  to  HBsAg-negative  and  anti-HBs 
positive  (9,5  UI/mL).  NUC  were  discontinued on 
September  2009.  One  year  later  the  patient  is  in 
hematological  remission,  while  both  HBsAg  and 
HBV-DNA remain negative. 
Case 2: In September 2006 a 73 year-old man was 
diagnosed  with  follicular  lymphoma  (grade-3a, 
stage III). Past  medical history was unremarkable 
and baseline US liver study was normal, ALT were 
normal, HBsAg and anti-HBe positive, and HBV-
DNA  persistently  below  2,000  IU/mL.  He  was 
categorized as inactive carrier and started on LAM 
before chemotherapy (6R-MINE: rituximab, mesna, 
ifosfamide,  mitroxantrone,  etoposide),  taken  until 
March  2007.  During  LAM  therapy  hematological
remission was obtained, ALT were normal,  while 
bilirubin  and  HBV-DNA  remained  slightly 
elevated.  In  July  2007,  the  patient  continued  the 
LAM treatment, and was admitted to the Liver Unit 
due  to  the  development  of  jaundice.  Lymphoma 
relapse  was  ruled  out,  but  signs  of  viral  and 
biochemical  breakthroughs  were  present.  Table  2
summarizes  the  disease  course.  Hepatic  failure,Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 2. Timeline of disease evolution. Case 2.
Date ALT
(U/l)
Bilirubin
(mg/dl)
Prothrombin time
(INR)
HBV DNA*
(IU/ml)
Therapy
9/03/2007 21 2.1 1.14 450 LAM 100 mg
10/07/2007 122 8.0 1.23 Nd
30/07/2007 200 27.3 1.6 1.470.000
2/08/2007 190 30.2 1.81 Nd LAM 100 mg + ADV 10 mg
21/08/2007 169 39.9 2.36 16.024 LAM 100 mg+ ADV 10 mg + PDN 50 mg
23/08/2007 181 42.5 2.26 Nd LAM 100 mg + ADV 10 mg + PDN 40 mg
26/08/2007 177 48.8 2.14 Nd
28/08/2007      166        49.7       2.29 Nd
30/08/2007      136       55.4      2.66 Nd LAM 100 mg + ADV 10 mg + PDN 30 mg
1/09/2007 132 55.7 3.30 Nd
2/09/2007     148     56.3 3.50 Nd Death
ALT:  serum  alanine  aminotransferase;  INR:  international  normalized  ratio;  LAM:  lamivudine;  ADV: adefovir  dipivoxil;  PDN: 
prednisolone; Nd: not determined; * Amplicor Roche PCR, Lower limit of detection <40 IU/ml.
mild portal encephalopathy, and ascites developed. 
LAM  resistance  (L80V,  L180M,  M204I)  was 
demonstrated  by  genotypic  analysis  (INNO-LiPA 
DR2),  and  ADV  (10  mg/day)  was  added.  Two 
weeks  later  viremia  significantly  decreased  but 
bilirubin, INR and ALT increased. The addition of 
PDN  (50  mg/day)  determined  a  slight  ALT 
decrease, however bilirubin and INR progressively 
worsened  and  the  patient  died  because  of 
irreversible liver failure. The autopsy revealed liver 
cirrhosis.
Discussion: During  chemotherapy  administration 
for onco-hematological  malignancies,  HBV 
replication  can reactivate in  overt  or occult  HBV 
carriers.  Active  viral  replication  reappears  during 
immunosuppression,  and  hepatocytes  infection 
occurs.
5 After the restoration of immune response, 
immune-mediated  destruction  of  infected 
hepatocytes can cause hepatitis, hepatic failure and 
even  death.
2 Pre-emptive  LAM  treatment  can 
reduce  reactivation  in  HBsAg-positive,  while 
universal prophylaxis in HBsAg-negative/anti-HBc-
positive remains controversial.
1 The available data 
regarding HBV reactivation rates in these patients 
range from 12% to 25%,
6-8 and have been obtained 
mainly from studies conducted on B-cell lymphoma 
patients, many of whom had been treated with the 
anti CD20 monoclonal antibody rituximab. In this 
setting LAM usually controls HBV replication and 
disease  evolution.
1,6,7 However,  a  severe  course 
despite adequate inhibition of viral replication can 
occur.
7,9-10 In fact, in the study by Yeo, the reported 
mortality  in  lymphoma  patients  sero-reverting  to 
HBsAg was 20%, despite LAM treatment.
7 In this 
study  HBV  reactivation  was  diagnosed  when  an 
increase in ALT (3-fold or greater or more than 100 
IU/L) was associated to HBsAg seroreversion and 
HBV-DNA increase.
7 Surveillance protocols based 
on HBV-DNA and anti-HBs level monitoring have 
been  proposed  to  detect  reactivation  of  viral 
replication at an earlier stage.
8 In the recent Niitsu 
paper,  this  approach allowed  to  detect virological 
reactivation  before  ALT  increase,  even  prior  to 
HBsAg  reappearance.  Patient  in  whom  HBV 
reactivation  was  detected  by  this  surveillance 
protocol were treated with entecavir, a more potent 
antiviral, and none developed acute hepatitis or died 
of  liver-related  causes.
8 Nevertheless,  the  cost-
effectiveness of this approach, based on high cost 
technologies  and  medications,  remains  to  be 
determined. At any rate, delayed detection of HBV 
reactivation,  and  the  consequent  unnoticed 
progression to acute hepatitis should be considered 
a risk factor for a worse clinical outcome, due to the 
late commencement of treatment,
7 as it happened in 
patient 1 due to his inability to attend the follow up 
appointments.  Similarly, the late identification of 
HBV mutants by genotypic analysis in suboptimal 
responders to  NUC plays a  pivotal role,  delaying 
appropriate  rescue  therapy  and  supporting  HBV 
reactivation, as it happened in patient 2. Therefore, 
these  situations  should  be  avoided,  appropriate 
surveillance  protocols  should  be  developed, 
enforcing  patients  to  adhere  to  follow  up. 
Glucocorticoids  addition  could  be  useful  in  this 
clinical  setting
3-5 as  these  drugs  blunt  T-cell 
response targeting HBV-infected hepatocytes.
11
Glucocorticoids use in the management of HBV 
reactivation  remains  anecdotal.  Early 
glucocorticoids  administration  to  manage  HBV 
reactivation has been described in a heterogeneous 
group  of  patients,  some  with  onco-hematological 
malignancies.
3,4 In  these  trials  pre-treatment 
baseline  HBV-DNA  and  liver disease status  were 
unknown,  no  case  of  isolated  anti-HBc  positive 
sero-reversion was included, management protocols 
varied  widely,  different  NUC  were  used  with  a Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
variable  sequence  of  glucocorticoids and  NUC 
introduction.
3,4 Nevertheless, these reports seem to 
suggest  that  a  key  strategy  is  the  timely 
consideration  of  glucocorticoids  addition  in  those 
cases  in  which  liver  functional  status  worsens  in 
spite of good virological response to NUC. In this 
case,  adding  glucocorticoids  might  combat  the 
harmful  effects  of  immune  reconstitution against 
HBV  infected  hepatocytes  in  onco-hematological 
malignancies, since NUC alone might not be able to 
control  the  progression  to  liver  failure  resulting 
from  hyperergic  reactions.
9,10 As  HBV  contains a 
glucocorticoid-responsive  element  that  may 
enhance viral replication favoring diffusion and the 
possible  emergence  of  resistant  strains,
12 these 
drugs should be introduced when one or more NUC 
have been started to control replication.
What emerges from our experience, is that 
the  presence  of  underlying  liver  disease  strongly 
influences  survival,  even  when  a  compound 
treatment (virologic and immunologic) is adopted. 
Thus, a careful evaluation of HBV markers, clinical 
history  and  direct/indirect  signs  of  silent  liver 
disease  is  mandatory  in  all  onco-hematological 
malignancies patients eligible for chemotherapy.
1
Conclusion: Our experience supports the policy of 
baseline  screening  of  onco-hematological 
malignancies patients  for  HBV  and  liver  disease 
status.
1 Prophylaxis is indicated in inactive carriers, 
and  could  be  considered  in  anti-HBc  positive 
subjects  with  onco-hematological  malignancies
and/or  bone  marrow  transplantation.  When 
biochemical  changes  do  not  improve  in  spite  of 
effective  virologic  response  to  NUC(s), 
glucocorticoids addition should be considered early 
in  order  to  control  hyperergic  immune  response. 
However,  prognosis  is  strictly  related  to  the 
underlying  liver  disease  status,  and  to  the  timely 
addition of glucocorticoids.
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